Pantetin

Pantetin
Nazivi
	IUPAC naziv N-[2-[2-[2-[3-(2,4-Dihidroksi-3,3-dimetil-butanoil)aminopropanoilamino ]etildisulfanil]etilkarbamoil]etil]-2,4-dihidroksi-3,3-dimetil-butanamid
	Drugi nazivi Bis-pantetin; koenzim pantetin
Identifikacija
CAS broj	16816-67-4 ;
3D model (Jmol)	interaktivna slika;
ChemSpider	4515 ;
ECHA InfoCard	100.037.114
PubChem C ID	4677;
UNII	7K81IL792L ;
	SMILES O=C(NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO)CCNC(=O)C(O)C(C)(C)CO; ; ; ; ; ;
Svojstva
Hemijska formula	C22H42N4O8S2
Molarna masa	554,723 g/mol
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

Pantetin (bis-pantetin, koenzimski pantetin) je dimerna forma pantotenske kiseline (vitamina B₅). On se sastoji od dva molekula pantotenske kiseline vezana cistaminskim grupama. Monomer ovog jedinjenja je poznat kao pantetein i on je intermedijer u produkciji koenzima u telu. Pantetin se smatra biološki aktivnijom formom vitamina B₅, ali je manje stabilan, i razlaže se tokom vremena, ako se ne čuva u frižideru.

Dijetarna suplementacija

Pantetin je dostupan kao dijetarni suplement jer postoje dokazi da je koristan za zdravlje. U više kliničkih ispitivanja na pacijentima sa povišenim nivoima holesterola i triglicerida, totalni i LDL holesterol su umanjeni za 12%, trigliceridi za 18%, i HDL holesterol je povišen za 9%.^[3]^[4] Ova klinička ispitivanja su sprovedena koristeći dnevne doze u opsegu od 600 do 1200 mg/dan. U tom opsegu doza nema evidencije o postojanju odnosa doze i efekta.^[5]

Dalja ispitivanja sa dozama u opsegu 600 - 900 mg/dan su pokazala statistički značajno sniženje nivoa LDL holesterola kod osoba sa znatno ili umereno povišenim nivoima lipida u krvi.^[6]

Reference

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Binaghi, P; Cellina, G; Lo Cicero, G; Bruschi, F; Porcaro, E; Penotti, M (1990). „Evaluation of the cholesterol-lowering effectiveness of pantethine in women in perimenopausal age”. Minerva medica. 81 (6): 475—9. PMID 2359503.
^ Arsenio, L; Bodria, P; Magnati, G; Strata, A; Trovato, R (1986). „Effectiveness of long-term treatment with pantethine in patients with dyslipidemia”. Clinical therapeutics. 8 (5): 537—45. PMID 3094958.
^ Gaddi, A; Descovich, GC; Noseda, G; Fragiacomo, C; Colombo, L; Craveri, A; Montanari, G; Sirtori, CR (1984). „Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia”. Atherosclerosis. 50 (1): 73—83. PMID 6365107. doi:10.1016/0021-9150(84)90009-1.
^ Rumberger, JA; Napolitano, J; Azumano, I; Kamiya, T; Evans, M (2011). „Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation”. Nutr Res. 31 (8): 608—15. PMID 21925346. doi:10.1016/j.nutres.2011.08.001.

Spoljašnje veze

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Binaghi, P; Cellina, G; Lo Cicero, G; Bruschi, F; Porcaro, E; Penotti, M (1990). „Evaluation of the cholesterol-lowering effectiveness of pantethine in women in perimenopausal age”. Minerva medica. 81 (6): 475—9. PMID 2359503.

[4] Arsenio, L; Bodria, P; Magnati, G; Strata, A; Trovato, R (1986). „Effectiveness of long-term treatment with pantethine in patients with dyslipidemia”. Clinical therapeutics. 8 (5): 537—45. PMID 3094958.

[5] Gaddi, A; Descovich, GC; Noseda, G; Fragiacomo, C; Colombo, L; Craveri, A; Montanari, G; Sirtori, CR (1984). „Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia”. Atherosclerosis. 50 (1): 73—83. PMID 6365107. doi:10.1016/0021-9150(84)90009-1.

[6] Rumberger, JA; Napolitano, J; Azumano, I; Kamiya, T; Evans, M (2011). „Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation”. Nutr Res. 31 (8): 608—15. PMID 21925346. doi:10.1016/j.nutres.2011.08.001.

[1]